Söndag 14 December | 12:36:00 Europe / Stockholm

Svenska | English

Regeneron

Kalender

	Est. tid*
2026-10-30	11:30	Kvartalsrapport 2026-Q3
2026-08-03	11:30	Kvartalsrapport 2026-Q2
2026-05-01	11:30	Kvartalsrapport 2026-Q1
2026-02-02	N/A	Bokslutskommuniké 2025
2025-11-20	-	X-dag kvartalsutdelning REGN 0.88
2025-10-28	-	Kvartalsrapport 2025-Q3
2025-08-18	-	X-dag kvartalsutdelning REGN 0.88
2025-08-01	-	Kvartalsrapport 2025-Q2
2025-06-13	-	Årsstämma
2025-05-20	-	X-dag kvartalsutdelning REGN 0.88
2025-04-29	-	Kvartalsrapport 2025-Q1
2025-02-20	-	X-dag bonusutdelning REGN 0.88
2025-02-04	-	Bokslutskommuniké 2024
2024-10-31	-	Kvartalsrapport 2024-Q3
2024-08-01	-	Kvartalsrapport 2024-Q2
2024-06-14	-	Årsstämma
2024-05-02	-	Kvartalsrapport 2024-Q1
2024-02-02	-	Bokslutskommuniké 2023
2023-11-02	-	Kvartalsrapport 2023-Q3
2023-08-03	-	Kvartalsrapport 2023-Q2
2023-06-09	-	Årsstämma
2023-05-04	-	Kvartalsrapport 2023-Q1
2023-02-03	-	Bokslutskommuniké 2022
2022-11-03	-	Kvartalsrapport 2022-Q3
2022-08-03	-	Kvartalsrapport 2022-Q2
2022-06-10	-	Årsstämma
2022-05-04	-	Kvartalsrapport 2022-Q1
2022-02-04	-	Bokslutskommuniké 2021
2021-11-04	-	Kvartalsrapport 2021-Q3
2021-08-05	-	Kvartalsrapport 2021-Q2
2021-06-11	-	Årsstämma
2021-05-06	-	Kvartalsrapport 2021-Q1
2021-02-05	-	Bokslutskommuniké 2020
2020-11-05	-	Kvartalsrapport 2020-Q3
2020-08-05	-	Kvartalsrapport 2020-Q2
2020-06-12	-	Årsstämma
2020-05-05	-	Kvartalsrapport 2020-Q1
2019-08-06	-	Kvartalsrapport 2019-Q2
2019-06-14	-	Årsstämma

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Filter

År

Typ

Språk

Rensa

2025-12-07 22:30:00 Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

2025-11-25 07:00:00 Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU) 782,76 USD | +3,23%

2025-11-19 22:10:00 EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications 705,49 USD | -2,13%

2025-11-19 13:00:00 Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation 705,49 USD | -2,13%

2025-11-13 13:00:00 Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs 704,81 USD | +2,76%

2025-11-08 16:46:31 Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet

2025-11-07 14:00:00 Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review 648,75 USD | -0,06%

2025-11-03 22:05:00 Regeneron Announces Investor Conference Presentations 632,26 USD | -2,75%

2025-10-31 12:00:00 Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award 650,11 USD | -0,94%

2025-10-28 11:30:00 Regeneron Reports Third Quarter 2025 Financial and Operating Results 644,39 USD | +10,82%

2025-10-17 13:30:19 Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation 577,72 USD | +1,62%

2025-10-15 13:00:41 Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers 579,55 USD | +2,16%

2025-10-12 16:18:30 DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

2025-10-08 20:31:53 Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation 586,30 USD | -0,46%

2025-09-30 22:05:00 Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 570,34 USD | +1,88%

2025-09-26 13:00:42 Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol 559,39 USD | -0,12%

2025-09-22 06:29:00 Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion 594,99 USD | -0,32%

2025-09-19 13:00:00 Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks 596,88 USD | +0,19%

2025-09-17 15:30:00 Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD 587,11 USD | +2,15%

2025-09-17 13:00:00 Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation 587,11 USD | +2,15%

2025-09-09 13:00:18 Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer 557,80 USD | +0,68%

2025-09-08 12:30:00 Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies 554,01 USD | -2,63%

2025-09-04 22:05:00 Regeneron Announces Updated Presentation Time for Upcoming Investor Conference 565,96 USD | -0,54%

2025-08-26 13:00:20 Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis 585,59 USD | -2,68%

2025-08-20 17:19:54 EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension 589,93 USD | +2,43%

2025-08-01 12:30:00 Regeneron Reports Second Quarter 2025 Financial and Operating Results 546,04 USD | -1,46%

2025-07-24 13:30:00 Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation 573,75 USD | +0,46%

2025-07-02 17:00:36 Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma 547,93 USD | +1,44%

2025-06-26 22:05:00 Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025 519,60 USD | +0,29%

2025-06-24 13:30:00 Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization 523,50 USD | +2,84%

2025-06-20 07:00:53 Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP) 508,52 USD | -0,50%

2025-06-15 17:21:00 Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

2025-06-08 00:30:00 Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

2025-06-02 13:05:33 Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist 494,57 USD | +0,88%

2025-05-31 14:04:38 Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

2025-05-30 07:00:00 Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials 490,26 USD | -17,84%

2025-05-22 23:00:13 Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma 593,81 USD | -1,03%

2025-05-19 13:07:52 Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness 593,56 USD | +0,28%

2025-05-16 17:24:49 75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition 591,90 USD | +1,86%

2025-05-15 20:02:43 Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments 581,09 USD | +0,31%

2025-05-01 15:30:00 Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination 583,85 USD | -0,54%

2025-05-01 15:00:00 Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases 583,85 USD | -0,54%

2025-04-29 12:30:00 Regeneron Reports First Quarter 2025 Financial and Operating Results 566,45 USD | -7,37%

2025-04-28 13:01:41 Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma 611,50 USD | +3,02%

2025-04-28 13:00:32 EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease 611,50 USD | +3,02%

2025-04-22 12:00:00 Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines 580,95 USD | +3,87%

2025-04-21 22:05:00 Regeneron Announces Investor Conference Presentations

2025-04-18 21:00:22 Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Regeneron

Kalender

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden